Managers / Q2 2024 · view latest →
Atlas Venture Life Science Advisors, LLC
CIK 0001917529 · 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE, MA, 02139 · (857) 201-2700
Summary
Atlas Venture Life Science Advisors, LLC reported $950M in U.S.-listed holdings across 15 positions for Q2 2024.
The portfolio is heavily concentrated: DYN alone accounts for 29.8% of reported value.
Compared with Q1 2024, the fund opened 1 new position and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 83.9% · $797M
- Other · 16.1% · $153M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TECXTectonic Therapeutics, Inc. | NEW | +378.4K | 378.4K | +$6M | $6M |
| AvroBio, Inc. | SOLD OUT | −4.54M | 0 | −$6M | $0 |
| Xilio Therapeutics, Inc. | SOLD OUT | −992.9K | 0 | −$1M | $0 |
| DNTHDianthus Therapeutics, Inc. | TRIMMED | −50.0K | 137.0K | −$2M | $4M |
| SPROSpero Therapeutics, Inc. | TRIMMED | −72.3K | 535.3K | −$349,157 | $695,937 |
| Aerovate Therapeutics, Inc. | TRIMMED | −240.0K | 1.80M | −$57M | $3M |
| IRONDisc Medicine, Inc. | ADDED | +222.2K | 2.51M | −$29M | $113M |
| KRROKorro Bio, Inc. | HELD | +17.9K | 1.14M | −$62M | $39M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | DYNDyne Therapeutics, Inc.history → | Common Stock | 29.80% | $283M | 8.02M |
| 2 | KYMRKymera Therapeutics, Inc.history → | Common Stock | 16.82% | $160M | 5.35M |
| 3 | Third Harmonic Bio, Inc. | Common Stock | 14.93% | $142M | 10.91M |
| 4 | IRONDisc Medicine, Inc.history → | Common Stock | 11.91% | $113M | 2.51M |
| 5 | DAWNGBXDay One Biopharmaceuticals, Inc.history → | Common Stock | 9.33% | $89M | 6.43M |
| 6 | KRROKorro Bio, Inc.history → | Common Stock | 4.06% | $39M | 1.14M |
| 7 | QTTBQ32 Bio, Inc.history → | Common Stock | 3.95% | $38M | 2.09M |
| 8 | Generation Bio, Co. | Common Stock | 2.46% | $23M | 8.28M |
| 9 | VIGLVigil Neuroscience, Inc.history → | Common Stock | 2.46% | $23M | 5.84M |
| 10 | REPLReplimune Group, Inc.history → | Common Stock | 1.99% | $19M | 2.10M |
| 11 | Ikena Oncology, Inc. | Common Stock | 0.87% | $8M | 5.02M |
| 12 | TECXTectonic Therapeutics, Inc. | Common Stock | 0.66% | $6M | 378.4K |
| 13 | DNTHDianthus Therapeutics, Inc. | Common Stock | 0.37% | $4M | 137.0K |
| 14 | Aerovate Therapeutics, Inc. | Common Stock | 0.31% | $3M | 1.80M |
| 15 | SPROSpero Therapeutics, Inc. | Common Stock | 0.07% | $695,937 | 535.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $790M | 6 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $865M | 8 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $753M | 9 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $662M | 11 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $522M | 13 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $820M | 13 | Feb 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $1.1B | 14 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $950M | 15 | Aug 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $1.1B | 16 | May 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $840M | 16 | Feb 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $646M | 15 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $804M | 15 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $739M | 16 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $830M | 17 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $906M | 17 | Nov 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $598M | 16 | Aug 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $791M | 17 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.